John Evans has been the CEO of Beam Therapeutics since January 2017, leading a company dedicated to developing innovative biotech solutions. With a strong background in biotechnology, he has played a significant role in advancing Beam's mission of providing life-long...

John Evans has been the CEO of Beam Therapeutics since January 2017, leading a company dedicated to developing innovative biotech solutions. With a strong background in biotechnology, he has played a significant role in advancing Beam's mission of providing life-long cures for serious diseases. Under his leadership, the company has made strides, including obtaining clearance from the FDA for their leading treatment for sickle cell disease. Evans has a solid resume, having worked as a senior VP at Agios Pharmaceuticals, and he has also been a Venture Partner at ARCH Venture Partners. His pay reflects his significant contributions with a total compensation of $1.13 million in 2023. Interestingly, despite fluctuations in the market, he gained $961,652 this year from stock that vested, showcasing the tangible results of his leadership. It's clear that Evans is focused, not just on immediate results, but on building an organization that's set for long-term success. You won't see him involved in short-selling or risky stock maneuvers; his approach is grounded and centered on performance-driven outcomes, which aligns with the company's goals.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

B

John Evans

CEO of Beam Therapeutics

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Beam Therapeutics for

4 years 3 months (Jan 2021 - Present)

Previous Experience

CEO of Beam Therapeutics Inc.

Rivals

Competitors/colleagues of John Evans

D

Alexander Schuth, M.D.

CEO of Denali Therapeutics Inc.

2022 Compensation

Stock

$0.00

Salary

$500.00K

Bonus

$225.00K

Other

$12.20K

Total Holdings

$10.84M

V

Rebecca Chambers

CEO of Veracyte

2023 Compensation

Stock

$0.00

Salary

$510.00K

Bonus

$388.49K

Other

$3.00K

Total Holdings

$4.42M

Holdings

See how much did John Evans make over time.

As of 2023, John Evans has shown considerable involvement with Beam Therapeutics through significant stock holdings, reflecting his commitment to the company. His wealth reached $961,652 from vested stock this year, despite an overall dip in the company's value. Notably,...

As of 2023, John Evans has shown considerable involvement with Beam Therapeutics through significant stock holdings, reflecting his commitment to the company. His wealth reached $961,652 from vested stock this year, despite an overall dip in the company's value. Notably, his stock compensation structure aligns with performance goals; he received no stock vested outside of cash bonuses this year, showcasing a strategic focus on immediate cash incentives rather than long-term capital gains. This pattern wasn't always the case—last year he also saw a substantial vested stock value totaling $2.2 million. His holdings exemplify careful risk management without speculative trading. Overall, Evans' portfolio indicates he is heavily invested in Beam's success, which has clear implications for the company's future.

Total Stock Sold

$29.21M

BEAM

$29.21M

556,017 BEAM shares

What if they kept their stock?

If John Evans didn't sell their stock, today they would have:
Extra BEAM556,017 shares worth $9.29M.
This is -68.22% and $19.93M less than what they got when they sold the stock.

Charitable Transactions

BEAM

12,000 shares

BEAM

Recent Charitable Transactions

BEAM

12,000 shares

BEAM

Jan 31, 2022

Charity

Insider Trading

See recent insider trades of John Evans.

BEAM

$1.47M

BEAM at $24.50/share

Jun 27, 2024

Sale

BEAM

$581.62K

BEAM at $32.13/share

Apr 1, 2024

Sale

BEAM

77,500 shares

BEAM

Mar 28, 2024

Received

BEAM

$2.03M

BEAM at $33.86/share

Mar 28, 2024

Sale

BEAM

$1.52M

BEAM at $25.33/share

Jan 31, 2024

Sale

BEAM

$346.14K

BEAM at $29.70/share

Apr 3, 2023

Sale

BEAM

56,250 shares

BEAM

Jan 31, 2023

Received

BEAM

225 shares

BEAM

Jan 31, 2023

Small Acquisition

BEAM

$2.32M

BEAM at $46.48/share

Oct 31, 2022

Sale

BEAM

$3.33M

BEAM at $66.55/share

Jul 28, 2022

Sale

Compensation History

See how much did John Evans make over time.

In 2023, John Evans received a total compensation package of $1,131,225, reflecting a base salary of $685,000 and a performance-based bonus of $431,550, which was 105% of target. This pay structure aligns with Beam’s focus on performance, incentivizing leadership that contributes to the company's strategic goals. He emphasizes cash compensation over stock outlets, with no stock grants this year, steering clear of volatility. His compensation is designed to attract and retain high-level talent, ensuring that executive pay mirrors performance metrics including research developments, organizational effectiveness, and financial targets. The compensation plan is centered on aligning executive interests with shareholder value, highlighting a straightforward philosophy: if the company does well, so do its leaders.

Year

2023

Total Compensation

$1.13M

Salary

$685.00K

Board Justification

The compensation philosophy is centered on pay for performance, aligning executive compensation with the achievement of corporate goals and stockholder value.

Bonus

$431.55K

Board Justification

Based on the achievement of corporate performance goals, resulting in a bonus of 105% of the target amount.

Other

$17.68K

Board Justification

Includes sabbatical payments, commuting benefits, 401(k) matching contributions, and a cell phone allowance.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and performance-based bonuses.

Performance Metrics

Performance metrics for 2023 included clinical, research and development, manufacturing, organizational, and financial goals.